Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials

Benzer Materyaller

• Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials
  Yazar:: Kashiwagi, Atsunori, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
  Yazar:: Kashiwagi, Atsunori, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
  Yazar:: Kashiwagi, A, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
  Yazar:: Saito, Masako, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
  Yazar:: Saito, Masako, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)